LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

Home・Elenco Azioni・Lantheus Holdings Inc

Lantheus Holdings Inc

Chiusa

SettoreSettore sanitario

100.02 4.14

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

94.71

Massimo

101.6

Metriche Chiave
By Trading Economics
Entrata	64M 118M
Vendite	-29M 377M
P/E Media del settore	23.181 49.888
EPS	1.46
Margine di Profitto	31.383
Dipendenti	1,193
EBITDA	-17M 81M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+7.69% upside

Dividendi
By Dow Jones
Utili prossimi	5 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	609M 6.3B
Apertura precedente	95.88
Chiusura precedente	100.02

Notizie sul Sentiment di mercato

By Acuity

50%

154 / 344 Classifica in Healthcare

Lantheus Holdings Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

3 giu 2026, 23:22 UTC

Utili

I principali Market Mover

Broadcom Shares Slide Despite Jump in 2Q Revenue on AI Chip Demand -- Update

3 giu 2026, 23:09 UTC

Azioni calde

Stocks to Watch: Broadcom, CrowdStrike, PVH, Petco

3 giu 2026, 20:51 UTC

Utili

Costco Reports 15% Sales Growth in May

3 giu 2026, 20:43 UTC

Utili

Broadcom 2Q Revenue Climbs on AI Chip Demand

3 giu 2026, 23:48 UTC

Discorsi di Mercato

Nikkei May Fall Amid Renewed Concerns About Iran Conflict -- Market Talk

3 giu 2026, 23:48 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

3 giu 2026, 23:35 UTC

Discorsi di Mercato

Oil Futures Fall on Possible Technical Correction -- Market Talk

3 giu 2026, 23:15 UTC

Discorsi di Mercato

Utili

Five Below, Broadcom and Crowdstrike Fall Despite Solid Results -- Market Talk

3 giu 2026, 22:08 UTC

Azioni calde

After-Hours Stocks to Watch: CrowdStrike, Broadcom, Five Below -- WSJ

3 giu 2026, 21:54 UTC

Discorsi di Mercato

Correction to Oil Futures Rise on Concerns About U.S.-Iran Talks Article on June 1

3 giu 2026, 21:18 UTC

Utili

Broadcom's Non-AI Semiconductor Revenue Rose 6% in 2Q, CEO Says

3 giu 2026, 21:15 UTC

Utili

Broadcom CEO: Google Partnership Continues to Be 'Very Substantial'

3 giu 2026, 21:13 UTC

Utili

Broadcom CEO Expects AI Semiconductor Revenue Growth to Continue in Fiscal 2028

3 giu 2026, 21:13 UTC

Utili

Broadcom Continues to Expect AI Semiconductor Revenue of More Than $100B in 2027, CEO Says

3 giu 2026, 21:12 UTC

Utili

Broadcom Expects AI Semiconductor Revenue of $56B This Year, CEO Says

3 giu 2026, 21:09 UTC

Utili

Broadcom CEO: Networking Made Up Almost 40% of AI Revenue in 2Q

3 giu 2026, 21:03 UTC

Utili

Broadcom Stock Falls After Earnings. Here's Why. -- Barrons.com

3 giu 2026, 20:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

3 giu 2026, 20:43 UTC

Utili

CrowdStrike Stock Falls Despite Earnings Beat -- Barrons.com

3 giu 2026, 20:39 UTC

Acquisizioni, Fusioni, Takeovers

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 4th Update

3 giu 2026, 20:37 UTC

Acquisizioni, Fusioni, Takeovers

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 3rd Update

3 giu 2026, 20:35 UTC

Utili

Broadcom Stock Falls Despite Record Results -- Barrons.com

3 giu 2026, 20:21 UTC

Acquisizioni, Fusioni, Takeovers

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 2nd Update

3 giu 2026, 20:17 UTC

Utili

Broadcom 2Q Semiconductor Solutions Revenue $15B >AVGO

3 giu 2026, 20:17 UTC

Utili

Broadcom Sees 3Q Semiconductor Revenue From AI $16B >AVGO

3 giu 2026, 20:15 UTC

Acquisizioni, Fusioni, Takeovers

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- Update

3 giu 2026, 20:15 UTC

Utili

Broadcom 2Q Adj EPS $2.44 >AVGO

3 giu 2026, 20:15 UTC

Utili

Broadcom 2Q EPS $1.91 >AVGO

3 giu 2026, 20:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

3 giu 2026, 20:15 UTC

Utili

Broadcom 2Q Rev $22.19B >AVGO

Confronto tra pari

Modifica del prezzo

Lantheus Holdings Inc Previsione

Obiettivo di Prezzo

By TipRanks

7.69% in crescita

Previsioni per 12 mesi

Media 103.71 USD 7.69%

Alto 115 USD

Basso 90 USD

Basato su 9 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Lantheus Holdings Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

9 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 9 che hanno fornito valutazioni azionarie a Lantheus Holdings Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

154 / 344 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Lantheus Holdings Inc

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.